Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
Go back to Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease| (NASDAQ: MNPR) | Delayed: 99.90 -1.55 (1.53%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $101.45 | 52 Week High | $ | |||
| Open | $103.33 | 52 Week Low | $ | |||
| Day High | $103.33 | P/E | N/A | |||
| Day Low | $98.90 | EPS | $ | |||
| Volume | 54,107 | |||||
